Earnings & Reporting

Panera revives its popular Asiago Bagel Stacks and launches new breakfast items, a strategic move to reclaim its bakery identity in a crowded market.

Iceland's Landsbankinn is set to auction highly-rated covered bonds, a key test of investor confidence amid recent central bank rate cuts.

As SKF readies its Q4 2025 report, all eyes are on its performance as a bellwether for global industry and a verdict on its major strategic overhaul.

Medallion Bank promotes from within, elevating key execs to steer its strategy in the specialized RV, boat, and home improvement lending markets.

The wellness firm secured a cash infusion by repricing options, a move that provides vital funds for its Zola brand but raises questions about dilution.

Petco is refinancing $1.5B in debt to extend maturities while reaffirming its financial outlook. Is this a sign of strength or underlying strain?

With preliminary Q1 revenue of $103.7M, Twist Bioscience beats forecasts, setting a bullish tone ahead of its full earnings report on February 2nd.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

With a major strategic pivot complete, Gibraltar Industries' leadership will outline its 2026 playbook to investors at a key 'New Ideas' conference.

Dolf van den Brink will step down in 2026 after a turbulent tenure, leaving an ambitious new strategy for his successor to execute amid market skepticism.

With its first MASH drug a success, Madrigal aims to redefine treatment by combining it with a newly licensed Pfizer asset. Is this the future?

As Encompass Health sets its Q4 earnings date, investors watch to see if the rehab giant can sustain its impressive 2025 growth amid industry pressures.

The semiconductor giant's stellar revenue, driven by a 19% surge in its core packaging business, confirms strong demand for AI and advanced tech.

After an eight-year tenure marked by growth, CFO Todd Garner announces his departure. CONMED projects stability by reaffirming its 2025 financial outlook.

Investors eye Arch Capital's Q4 results after a stellar Q3, seeking clues on its resilience amid shifting insurance and reinsurance market dynamics.

Amid declining sales and a falling stock price, USANA brings back former CEO Kevin Guest to steer the company, replacing Jim Brown after a tough three-year tenure.

The opioid treatment specialist projects over $1.1B in revenue, driven by its flagship drug SUBLOCADE and a major strategic overhaul in the U.S.

Biotech leader Arrowhead Pharmaceuticals prices upsized offerings, signaling strong investor confidence and fueling its next wave of RNAi therapies.

With its CEO stepping down, Lifeist Wellness tasks its CFO with a dual role, signaling a push for stability as it navigates a tough market.

The shipping giant cashes in on eight older vessels, using a massive profit to slash debt, reward shareholders, and accelerate its sustainable fleet strategy.